NVST vs ZBH
Envista Holdings vs Zimmer Biomet — AI-powered side-by-side comparison
NVST
Envista Holdings
66
Buy
VS
| Metric | NVST | ZBH |
|---|
| AI Score |
66
|
70
|
| Price |
$28.14
|
$96.61
|
| P/E Ratio |
47.71×
|
23.38×
|
| ROE |
1.5%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
55.5%
|
69.9%
|
| Debt / Equity |
0.52×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
58.7
|
58.9
|
| Beta |
0.861
|
0.468
|
| Expected Upside |
+1.7%
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for NVST versus ZBH.
ZBH leads by 4 points.
ZBH scores 70/100 (Buy) versus NVST at 66/100 (Buy).
NVST Committee View
80% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is p/e of 66.8 is expensive by classic value standards. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 66.8 is expensive by classic value standards — Value
- ROE of only 2.2% -- cheap may mean cheap for a reason — Value
ZBH Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 11.2% downside vs 1.2% upside.